MRNA

By Denny Jacob

Moderna Inc. shares edged down 5.9% to $162 in after-hours trading Thursday following mixed results of an experimental Moderna vaccine against seasonal influenza in a clinical trial of more than 6,100 adults in the southern hemisphere.

The pharmaceutical company's Moderna shot induced superior or roughly equal immune responses to two of four targeted flu strains, compared with licensed flu vaccines. These two flu strains cause most flu cases in older adults. But Moderna's vaccine induced inferior immune responses to the other two strains, which are more frequent in younger people.

The company expects interim results by the end of March from a second, larger study testing how well the vaccine prevented flu cases in people in the northern hemisphere. If positive, Moderna could file for U.S. regulatory approval of the shot, though it is unlikely it would be cleared for wide use before the next flu season in the fall, Moderna President Stephen Hoge told The Wall Street Journal.

Write to Denny Jacob at denny.jacob@wsj.com

(END) Dow Jones Newswires

February 16, 2023 16:34 ET (21:34 GMT)

Moderna (NASDAQ:MRNA)
Gráfico Histórico do Ativo
De Mai 2023 até Jun 2023

Moderna (NASDAQ:MRNA)
Gráfico Histórico do Ativo
De Jun 2022 até Jun 2023